TY - JOUR
T1 - Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients
AU - LaPorte, David J.
AU - Lahti, Adrianne C.
AU - Koffel, Bettylou
AU - Tamminga, Carol A.
N1 - Funding Information:
Acknowledgement~The authors would like to thank the patients and staff of the Residential Treatment Unit of the Maryland Psychiatric Research Center for their participation in this project. The helpful comments of Ann Summerfelt are gratefully acknowledged. This work was supported, in part, by the National Institute of Mental Health Grant (MH CRC 40279).
PY - 1996
Y1 - 1996
N2 - Glutamatergic dysfunction may play an important role in both the pathophysiology of schizophrenia, and impaired memory commonly observed in that disorder. NMDA receptor antagonists impair learning/memory in animal models, putatively based on its ability to block long-term potentiation (LTP) in the hippocampus. Although well studied in animal models, research in humans is limited and confounded by administration of NMDA antagonists before the learning experience. Based on presumed glutamatergic dysfunction, it was predicted that the NMDA antagonist ketamine would not effect memory in schizophrenic subjects. Bolus injections of ketamine (0.5 mg/kg) or placebo were given to seven patients with schizophrenia in this double-blind cross-over study. Immediately prior to injection, subjects were administered verbal and figural memory tests. Delayed recalls were obtained 30-45 min postinjection. In order to rule out drug-induced generalized cognitive impairments, other cognitive tasks were administered pre- and postinjection. The results indicate no differences between the drug and placebo conditions for either memory task, and no changes on the other cognitive tasks observed.
AB - Glutamatergic dysfunction may play an important role in both the pathophysiology of schizophrenia, and impaired memory commonly observed in that disorder. NMDA receptor antagonists impair learning/memory in animal models, putatively based on its ability to block long-term potentiation (LTP) in the hippocampus. Although well studied in animal models, research in humans is limited and confounded by administration of NMDA antagonists before the learning experience. Based on presumed glutamatergic dysfunction, it was predicted that the NMDA antagonist ketamine would not effect memory in schizophrenic subjects. Bolus injections of ketamine (0.5 mg/kg) or placebo were given to seven patients with schizophrenia in this double-blind cross-over study. Immediately prior to injection, subjects were administered verbal and figural memory tests. Delayed recalls were obtained 30-45 min postinjection. In order to rule out drug-induced generalized cognitive impairments, other cognitive tasks were administered pre- and postinjection. The results indicate no differences between the drug and placebo conditions for either memory task, and no changes on the other cognitive tasks observed.
UR - http://www.scopus.com/inward/record.url?scp=0030248928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030248928&partnerID=8YFLogxK
U2 - 10.1016/0022-3956(96)00018-0
DO - 10.1016/0022-3956(96)00018-0
M3 - Article
C2 - 8923336
AN - SCOPUS:0030248928
SN - 0022-3956
VL - 30
SP - 321
EP - 330
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
IS - 5
ER -